Compare CDNA & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | VCEL |
|---|---|---|
| Founded | 1998 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2007 | 1996 |
| Metric | CDNA | VCEL |
|---|---|---|
| Price | $53.96 | $39.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $28.00 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 1.0M | 455.8K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 2.13 | N/A |
| Revenue | $48,324,000.00 | ★ $276,259,000.00 |
| Revenue This Year | $16.01 | $19.40 |
| Revenue Next Year | $11.31 | $18.24 |
| P/E Ratio | $25.48 | ★ N/A |
| Revenue Growth | ★ 18.93 | 16.45 |
| 52 Week Low | $13.95 | $28.95 |
| 52 Week High | $55.16 | $49.32 |
| Indicator | CDNA | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 69.87 | 42.76 |
| Support Level | $45.74 | $35.32 |
| Resistance Level | N/A | $41.25 |
| Average True Range (ATR) | 2.17 | 1.23 |
| MACD | -0.00 | 0.15 |
| Stochastic Oscillator | 85.84 | 63.53 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.